Literature DB >> 18615179

Cell and gene therapies for refractory epilepsy.

Detlev Boison1.   

Abstract

Despite recent advances in the development of antiepileptic drugs, refractory epilepsy remains a major clinical problem affecting up to 35% of patients with partial epilepsy. Currently, there are few therapies that affect the underlying disease process. Therefore, novel therapeutic concepts are urgently needed. The recent development of experimental cell and gene therapies may offer several advantages compared to conventional systemic pharmacotherapy: (i) Specificity to underlying pathogenetic mechanisms by rational design; (ii) specificity to epileptogenic networks by focal delivery; and (iii) avoidance of side effects. A number of naturally occurring brain substances, such as GABA, adenosine, and the neuropeptides galanin and neuropeptide Y, may function as endogenous anticonvulsants and, in addition, may interact with the process of epileptogenesis. Unfortunately, the systemic application of these compounds is compromised by limited bioavailability, poor penetration of the blood-brain barrier, or the widespread systemic distribution of their respective receptors. Therefore, in recent years a new field of cell and gene-based neuropharmacology has emerged, aimed at either delivering endogenous anticonvulsant compounds by focal intracerebral transplantation of bioengineered cells (ex vivo gene therapy), or by inducing epileptogenic brain areas to produce these compounds in situ (in vivo gene therapy). In this review, recent efforts to develop GABA-, adenosine-, galanin-, and neuropeptide Y- based cell and gene therapies are discussed. The neurochemical rationales for using these compounds are discussed, the advantages of focal applications are highlighted and preclinical cell transplantation and gene therapy studies are critically evaluated. Although many promising data have been generated recently, potential problems, such as long-term therapeutic efficacy, long-term safety, and efficacy in clinically relevant animal models, need to be addressed before clinical applications can be contemplated.

Entities:  

Keywords:  adenosine; epileptogenesis; Epilepsy; GABA; cell therapy; galanin; gene therapy; neuropeptide Y

Year:  2007        PMID: 18615179      PMCID: PMC2435346          DOI: 10.2174/157015907780866938

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


  170 in total

Review 1.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

2.  Seizure suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia nigra.

Authors:  W Löscher; U Ebert; H Lehmann; C Rosenthal; G Nikkhah
Journal:  J Neurosci Res       Date:  1998-01-15       Impact factor: 4.164

Review 3.  Current treatments of epilepsy.

Authors:  Siddhartha Nadkarni; Josiane LaJoie; Orrin Devinsky
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

Review 4.  Neuropeptide Y: the universal soldier.

Authors:  T Pedrazzini; F Pralong; E Grouzmann
Journal:  Cell Mol Life Sci       Date:  2003-02       Impact factor: 9.261

5.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.

Authors:  L Naldini; U Blömer; F H Gage; D Trono; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Hematopoietic potential of stem cells isolated from murine skeletal muscle.

Authors:  K A Jackson; T Mi; M A Goodell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

7.  Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy.

Authors:  YogendraSinh H Raol; Ingrid V Lund; Sabita Bandyopadhyay; Guojun Zhang; Daniel S Roberts; John H Wolfe; Shelley J Russek; Amy R Brooks-Kayal
Journal:  J Neurosci       Date:  2006-11-01       Impact factor: 6.167

8.  Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion.

Authors:  Rebecca P Haberman; R Jude Samulski; Thomas J McCown
Journal:  Nat Med       Date:  2003-07-13       Impact factor: 53.440

9.  Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis.

Authors:  Nicolette Gouder; Louis Scheurer; Jean-Marc Fritschy; Detlev Boison
Journal:  J Neurosci       Date:  2004-01-21       Impact factor: 6.167

10.  Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats.

Authors:  Nelson Rebola; Joana E Coelho; Ana Rita Costenla; Luísa V Lopes; António Parada; Catarina R Oliveira; Patrício Soares-da-Silva; Alexandre de Mendonça; Rodrigo A Cunha
Journal:  Eur J Neurosci       Date:  2003-08       Impact factor: 3.386

View more
  22 in total

1.  Adenosine kinase as a target for therapeutic antisense strategies in epilepsy.

Authors:  Panos Theofilas; Sukhmani Brar; Kerry-Ann Stewart; Hai-Ying Shen; Ursula S Sandau; David Poulsen; Detlev Boison
Journal:  Epilepsia       Date:  2011-01-28       Impact factor: 5.864

Review 2.  Gene therapy for epilepsy.

Authors:  David W McCandless; Jeffrey W McCandless
Journal:  Metab Brain Dis       Date:  2010-09-23       Impact factor: 3.584

Review 3.  Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.

Authors:  Detlev Boison
Journal:  Epilepsy Res       Date:  2009-05-09       Impact factor: 3.045

4.  Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis.

Authors:  Tianfu Li; Gaoying Ren; David L Kaplan; Detlev Boison
Journal:  Epilepsy Res       Date:  2009-02-12       Impact factor: 3.045

Review 5.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

6.  Astrocytes derived from fetal neural progenitor cells as a novel source for therapeutic adenosine delivery.

Authors:  Annelies Van Dycke; Robrecht Raedt; Alain Verstraete; Panos Theofilas; Wytse Wadman; Kristl Vonck; Detlev Boison; Paul Boon
Journal:  Seizure       Date:  2010-06-17       Impact factor: 3.184

7.  GABAB Receptor Blockade Prevents Antiepileptic Action of Ghrelin in the Rat Hippocampus.

Authors:  Zohreh Ataie; Shirin Babri; Mina Ghahramanian Golzar; Hadi Ebrahimi; Fariba Mirzaie; Gisou Mohaddes
Journal:  Adv Pharm Bull       Date:  2013-08-20

8.  Glycine transporter 1 is a target for the treatment of epilepsy.

Authors:  Hai-Ying Shen; Erwin A van Vliet; Kerry-Ann Bright; Marissa Hanthorn; Nikki K Lytle; Jan Gorter; Eleonora Aronica; Detlev Boison
Journal:  Neuropharmacology       Date:  2015-08-21       Impact factor: 5.250

9.  Comonitoring of adenosine and dopamine using the Wireless Instantaneous Neurotransmitter Concentration System: proof of principle.

Authors:  Young-Min Shon; Su-Youne Chang; Susannah J Tye; Christopher J Kimble; Kevin E Bennet; Charles D Blaha; Kendall H Lee
Journal:  J Neurosurg       Date:  2010-03       Impact factor: 5.115

Review 10.  Adenosine as a neuromodulator in neurological diseases.

Authors:  Detlev Boison
Journal:  Curr Opin Pharmacol       Date:  2007-10-17       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.